Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor.
Phase of Trial: Phase I/II
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Pasireotide (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Aug 2017 Status changed from completed to discontinued as the PI had passed away.
- 26 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2013 Planned end date changed from 1 Oct 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.